New drug cocktail shows promise for Hard-to-Treat cancers

NCT ID NCT04282018

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe doses and check for side effects. The study did not fully determine the best dose, but it gathered important safety information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGB-10188 (a PI3Kδ inhibitor) combined with zanubrutinib or tislelizumab
What this could lead to: If successful, this could lead to a new treatment option for certain blood cancers and solid tumors that have not responded to prior therapy.
What could go wrong: This is an early-phase trial with only 97 participants, and the recommended dose was not fully determined. Side effects are possible, and the combinations may not prove effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma follicular lymphoma Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma marginal zone lymphoma neoplasm ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B CELL LYMPHOMA FOLLICULAR LYMPHOMA MANTLE CELL LYMPHOMA MARGINAL ZONE LYMPHOMA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Show contact details

Locations

Affiliated Zhongshan Hospital of Fudan University

Shanghai, Shanghai Municipality, 200032, China
Austin Health

Heidelberg, Victoria, 3084, Australia
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Blacktown Cancer and Haematology Centre

Blacktown, New South Wales, 2148, Australia
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200000, China
Fujian Cancer Hospital

Fuzhou, Fujian, 350014, China
Gallipoli Medical Research Foundation

Greenslopes, Queensland, 4120, Australia
General Hospital of Ningxia Medical University

Yinchuan, Ningxia, 750004, China
Henan Cancer Hospital

Zhengzhou, Henan, 450000, China
Hubei Cancer Hospital

Wuhan, Hubei, 430079, China
Jining No Peoples Hospital West Branch

Jining, Shandong, 272000, China
Monash Health

Clayton, Victoria, 3168, Australia
Peking University Shenzhen Hospital

Shenzhen, Guangdong, 518036, China
Perth Blood Institute

West Perth, Western Australia, 6005, Australia
Pindara Private Hospital

Benowa, Queensland, 4217, Australia
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Saint Vincents Hospital Sydney

Darlinghurst, New South Wales, 2010, Australia
The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, 325000, China
The First Hospital of Jilin University

Changchun, Jilin, 130021, China
The Third Xiangya Hospital of Central South University

Changsha, Hunan, 410013, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China
Zhejiang University College of Medicine Second Affiliated Hospital

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.